NIH's Clot-Busting Antibodies Free for Cancer-COVID License
Published Date: 8/12/2026
Notice
Summary
Scientists at the National Cancer Institute (NCI) have discovered a novel therapeutic, diagnostic and prognostic target for thrombosis: Soluble Tissue Factor (sTF). NCI has generated first-in- class antibodies and platform selectively neutralizing pathological coagulation while preserving normal hemostasis. This platform technology can be used to prevent, diagnose and treat pathological thrombosis caused by a variety of clinical conditions-including cancer, sepsis, infectious diseases (e.g., COVID), autoimmune disorders, trauma, heart conditions and inflammatory conditions. It offers a much more sensitive and specific test of thrombosis than the current D-dimer test. It may be applicable to any clinical condition which induces necroptosis, pyroptosis and NETtosis, such as cancer, neurodegenerative disease, ischemia-reperfusion and acute injuries, traumatic injuries, bacterial and viral infections, cardiovascular conditions, and atherosclerosis, inflammatory, autoimmune conditions, and others.
Analyzed Economic Effects
3 provisions identified: 3 benefits, 0 costs, 0 mixed.
NCI Offering sTF Licensing Opportunity
The National Cancer Institute (NCI) is offering its soluble tissue factor (sTF) humanized monoclonal antibodies and related diagnostic and therapeutic methods for licensing or collaborative development. Partnership opportunities explicitly include preclinical optimization, clinical development, and diagnostic assay co-development.
Potentially More Accurate Thrombosis Test
The NCI describes soluble tissue factor (sTF) as offering a much more sensitive and specific test of thrombosis than the current D-dimer test. This discovery is presented as a basis for diagnostic tools such as ELISA and point-of-care assays for earlier detection and monitoring of thrombosis.
Safer Anti-Thrombosis Therapeutic Approach
NCI reports humanized monoclonal antibodies that selectively neutralize soluble tissue factor (sTF) can block pathological thrombosis without systemic anticoagulation and while preserving normal hemostasis. The notice describes in vivo validation showing prevention of fibrinogen depletion and normalization of coagulation parameters.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-19718, Center for Scientific Review; Notice of Closed Meetings
The NIH’s Center for Scientific Review is holding two closed virtual meetings in October 2026 to review important grant applications. These meetings protect private info and trade secrets while deciding which research projects get funding. Scientists and research teams applying for grants should note these dates as they impact funding decisions but don’t involve public attendance.
2026-19804, Submission for OMB Review; 30-Day Comment Request; Generic Clearance for NIH Citizen Science and Crowdsourcing Projects (Office of the Director)
The NIH is asking for approval to keep collecting info from citizen science and crowdsourcing projects, making it easier to gather public input on health research. This affects anyone involved in these projects and invites comments by October 28, 2026. No new costs or big changes, just a smooth way to keep the data flowing for better science!
2026-19719, Center for Scientific Review; Amended Notice of Meeting
The NIH’s Center for Scientific Review is shortening a key meeting from two days to just one day on October 13, 2026, keeping the same 9 a.m. to 6 p.m. hours. This change affects members of the Surgical Sciences and Bioengineering review group and means less time in the room but no public access. No money changes or delays are expected—just a quicker, tighter meeting!
2026-19706, Draft NIH Policy on Sharing Summary Level Study Results With Clinical Research Participants
The NIH wants to make it easier for people who join clinical studies to get simple summaries of the study results. This new policy aims to boost trust and teamwork between researchers and participants, helping science move faster and better. They’re asking for your thoughts by October 26, 2026, so get ready to share your ideas!
2026-19431, Government-Owned Inventions; Availability for Licensing
The government is offering a new invention for licensing that makes stem cell transplants safer and less harsh, especially for leukemia patients and older folks. This tech uses a special protein to prepare patients for transplants without the tough side effects of chemo and radiation. Companies can start licensing this preclinical innovation now to help bring better treatments to market faster.
2026-19303, Submission for OMB review; 30-Day Comment Request; the Impact and Costs of Promoting Objectivity in Research 42 CFR Part 50 Subpart F and Responsible Prospective Contractors 45 CFR Part 94 (Office of the Director)
The National Institutes of Health (NIH) is asking for your thoughts on how they collect info to keep research honest and fair. This affects researchers and contractors who work with NIH, aiming to make sure everything stays clear and trustworthy. You’ve got until October 22, 2026, to share your comments—no cost changes, just a check-in to keep things running smoothly!
Previous / Next Documents
Previous: 2026-16439, Government Owned Invention Available for License: Quantitative Particle Identification (QPID) Digital Autoradiography System
The National Cancer Institute (NCI) seeks research co- development partners and/or licensees for a QPID digital autoradiography system with particle identification capabilities.
Next: 2026-16441, Government Owned Invention Available for License: DNA Methylation-Based Cancer Diagnostics for Accurate Tumor Classification
This technology encompasses a DNA methylation-based diagnostic platform designed to improve the accuracy and consistency of cancer classification, with demonstrated utility for tumors of the central nervous system, kidney, and hematopoietic system. By identifying disease-specific methylation signatures, the approach reduces interobserver variability and enhances diagnostic confidence. The central nervous system (CNS) classifier is built from a curated reference set of 16,567 methylation profiles and organizes tumors into 22 families and 133 clinically relevant diagnostic classes, including 21 newly developed methylation classes not represented in other existing tools. Across multiple independent validation cohorts (n = 5,875), the classifier demonstrated robust performance, and in a clinical-impact analysis of 1,204 NIH validation cases, methylation profiling materially influenced final diagnosis in 74.4% of cases by refining, increasing precision, or reclassifying. The CNS classifier was deployed as a user-facing software tool, MethylScape Analysis, which streamlines methylation-based classification workflows for CNS tumors, https://methylscape.ccr.cancer.gov/. The development of multiple specialized classifiers supports a more granular understanding of tumor biology and informed clinical decision-making.